Age‐Related Outcomes of Valve‐in‐Valve Transcatheter Aortic Valve Replacement for Structural Valve Deterioration
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.037168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Takashi Nagasaka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center Smidt Heart Institute Los Angeles CA USA. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve, Heart Valve Prosthesis, Aortic Valve Stenosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Valve‐in‐valve transcatheter aortic valve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration. In this study, we aimed to examine the outcomes of valve‐in‐valve TAVR across different age groups to understand the age‐related clinical outcomes of treating structural valve deterioration following surgical aortic valve replacement and TAVR. Methods and Results In this retrospective study, we included patients who underwent valve‐in‐valve TAVR at our center. We compared procedural complications and clinical outcomes among patients 85 years of age, no significant differences in the incidence of stroke/transient ischemic attack were observed among age groups. All groups exhibited significant improvements in valve hemodynamics that persisted for 3 years. Although leaflet thrombosis assessed using computed tomography imaging 30 days post‐TAVR was more prevalent in the older group, age was not an independent predictor of this outcome.
Conclusions
Valve‐in‐valve TAVR was associated with an increased 3‐year mortality risk among older patients despite consistent hemodynamic benefits across all age groups. Age‐related differences in leaflet thrombosis did not predict hypoattenuated leaflet thickening, indicating that further studies are necessary to elucidate its implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cedars-Sinai Medical Center Smidt Heart Institute Los Angeles CA USA.
- Department of Cardiovascular Medicine Gunma University Graduate School of Medicine Maebashi, Gunma Japan.
- Faculty of Medicine Tel Aviv University Tel Aviv Israel.
- Bruce Rappaport Faculty of Medicine Technion Israel Institute of Technology Haifa Israel.
ORCID-Profile: Vivek Patel, Kazuki Suruga, Alon Shechter, Hideki Ishii, Hasan Jilaihawi, Mamoo Nakamura
Zitieren
APA
Nagasaka, T., Patel, V., Suruga, K., Shechter, A., Koren, O., Chakravarty, T., Cheng, W., Ishii, H., Jilaihawi, H., Nakamura, M., & Makkar, R. R. (2025). Age‐Related Outcomes of Valve‐in‐Valve Transcatheter Aortic Valve Replacement for Structural Valve Deterioration. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.037168
Vancouver
Nagasaka T, Patel V, Suruga K, Shechter A, Koren O, Chakravarty T, et al. Age‐Related Outcomes of Valve‐in‐Valve Transcatheter Aortic Valve Replacement for Structural Valve Deterioration. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.037168
BibTeX
@article{Nagasaka2025,
author = {Nagasaka, Takashi and Patel, Vivek and Suruga, Kazuki and Shechter, Alon and Koren, Ofir and Chakravarty, Tarun and Cheng, Wen and Ishii, Hideki and Jilaihawi, Hasan and Nakamura, Mamoo and Makkar, Raj R},
title = {Age‐Related Outcomes of Valve‐in‐Valve Transcatheter Aortic Valve Replacement for Structural Valve Deterioration},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.037168}
}
EUVIMED